

## MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	248	241	40	20	11	4	1	09/19/2014	234	98
						241	40	20	11	4	1			
		2	Y 2	Continuous Dosing	216	101	19	7	6	2	1	09/19/2014		
				3 Intermittent Dosing		98	20	8	8	4	0			
						199	39	15	14	6	1			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	19	13	5	2	1	1	02/06/2017	90	41
						19	13	5	2	1	1			
	S1607-MELAN, Adv, T-VEC, MK-3475	1	Y 1	T-VEC + MK-3475(pembrolizumab)	64	12	12	10	4	1	1	06/05/2018	32	19
						12	12	10	4	1	1			
	S1616-MELAN, Adv, Ipilimumab ± Nivolumab	1	Y 1	Ipilimumab	94	8	6	0	0	0	0	10/23/2017	271	109
				2 Nivolumab + Ipilimumab		22	17	8	4	1	0			
						30	23	8	4	1	0			
	S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab	1	Y 1	Adjuvant Arm	556	1	1	1	1	1	0	02/15/2019	135	52
						1	1	1	1	1	0			
		2	Y 3	Surgery	556	1	1	1	1	1	1	02/15/2019		
						1	1	1	1	1	1			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		33	9	6	3	3	1	11/03/2015	365	144
						33	9	6	3	3	1			
		2	E	Total Registrations		12	6	1	0	0	0	11/03/2015		
						12	6	1	0	0	0			
	EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	0	0	0	0	0	03/25/2016	225	94
						36	0	0	0	0	0			

**23-FEB-2019 6:10**  
**MELAN Open Studies with No Registrations**

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab	3 Adjuvant Therapy	06-Dec-18